Tag Archives: NASDAQ:ZGNX

Zogenix (NASDAQ:ZGNX) Post Smaller Loss in Fiscal Q4; Ends Marketing Partnership – ZGNX, AGN, ENDP, ALKS

Posted on March 16, 2013 by Thomas Vedder

The SAN DIEGO, California based Zogenix, Inc (NASDAQ:ZGNX) announced on Friday that it had a smaller loss in fiscal Q4 after it finished a marketing partnership on its injectable migraine treatment, Sumavel DosePro.

Zogenix ended a marketing partnership with Japanese …

Posted in Healthcare, Latest Headlines | Tagged AGN, Alkermes, ALKS, Allergan, Endo Health, ENDP, NASDAQ:ALKS, NASDAQ:ENDP, NASDAQ:ZGNX, NYSE:AGN, ZGNX, Zogenix | Comments Off

U.S. Stock Market Movers Overview: LinkedIn (NYSE:LNKD), DISH Network (NASDAQ:DISH) – LNKD, DISH, DIS, ZGNX, PAL, CBB

Posted on February 28, 2013 by Thomas Vedder

Investors responded positively to overall marker on Wednesday. Key movement were monitored in Zogenix, Inc (NASDAQ:ZGNX) and North American Palladium Ltd (USA) (NYSE:PAL) on percentage gainers side while Cincinnati Bell Inc (NYSE:CBB) was major percentage decliner.

LinkedIn Corp (NYSE:LNKD) stock …

Posted in Latest Headlines, Services | Tagged CBB, Cincinnati Bell, DIS, DISH, Dish Network, Linkedin, LNKD, NASDAQ:DISH, NASDAQ:ZGNX, North American Palladium, NYSE:CBB, NYSE:DIS, NYSE:LNKD, NYSE:PAL, PAL, Walt Disney, ZGNX, Zogenix | Comments Off

MAP Pharmaceuticals (NASDAQ:MAPP) Wins FDA Approval for Levadex; Stock Hikes – MAPP, AGN, PATH, ZGNX

Posted on November 26, 2012 by Thomas Vedder

The Mountain View, California based MAP Pharmaceuticals Inc’s (NASDAQ:MAPP) stock hiked on Friday after encouraging regulatory news on what could become the corporation’s primary approved product.

MAP reported that the United States Food and Drug Administration permitted the drug developer’s …

Posted in Healthcare, Latest Headlines | Tagged AGN, Allergan, Map Pharmaceuticals, MAPP, NASDAQ:MAPP, NASDAQ:PATH, NASDAQ:ZGNX, NuPathe, NYSE:AGN, PATH, ZGNX, Zogenix | Comments Off

Soaring stocks and the reasons why (DNDN, JAZZ, ZGNX)

Posted on January 6, 2012 by Cameron White

In this article: Dendreon Corporation (NASDAQ:DNDN), Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zogenix (NASDAQ:ZGNX).

Dendreon Corporation (NASDAQ:DNDN) shares continued to climb today after the company announced yesterday that sales of its prostate-cancer therapy Provenge have continued to grow in the fourth quarter. …

Posted in Latest Headlines, Reports | Tagged acquisition, analyst, Azur Pharma, company, coverage, Dendreon Corporation, DNDN, earnings, expectations, fiscal, forecast, JAZZ, Jazz Pharmaceuticals, NASDAQ:DNDN, NASDAQ:JAZZ, NASDAQ:ZGNX, provenge, quarter, rating, revenue, sales, shares, stock, william blair, ZGNX, Zogenix | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.